Highlights Newsletter 2
This newsletter presents you the following key sessions:
3. IMpower010; Atezolizumab significantly improves disease-free survival in stage II-IIIA NSCLC
This newsletter presents you the following key sessions:
3. IMpower010; Atezolizumab significantly improves disease-free survival in stage II-IIIA NSCLC
Medical writer
Medical writer